Not Tagged
novocure
['lunar ']
#asco23 the phase iii lunar trial met its primary endpoint and is a positive study of ttfields. in my opinion, this is not yet part of soc. outdated control arm. os difference could easily be small imbalance in pdl1, egfr, alk - which all impact io outcomes. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo